Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ADiRaS

Financiado

Alzheimer s Disease Diagnosis by Spectroscopy. Accurate and Non Invasive Medical...

Alzheimer s Disease Diagnosis by Spectroscopy. Accurate and Non Invasive Medical Device for the Diagnosis of Early Stage Alzheimer s Disease. Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to... ver más

31/10/2015

RAMAN HEALTH TECHN...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

RAMAN HEALTH TECHNOLOGIES El desarrollo de una nueva tecnología basada en espectroscopia raman y espectroscopia de infrarrojo para aplicaciones biomédicas, así como e...

TRL 3-4 | 603K€

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-10-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

PHC-12-2015-1: Clinical research for the validation of biomarkers and/or diagnostic medical devices

I+D

Cerrada hace 9 años

0% 70% 100%

1 Participantes

RAMAN HEALTH TECHNOLOGIES

50.00K€ | Lider

Últimas noticias

30-11-2024: Cataluña Gestión For... Se ha cerrado la línea de ayuda pública: Gestión Forestal Sostenible para Inversiones Forestales Productivas para el organismo:

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

Duración del proyecto: 4 meses Fecha Inicio: 2015-06-04
Fecha Fin: 2015-10-31

Líder del proyecto

RAMAN HEALTH TECHNOLOGIES

TRL 3-4 | 603K€

Presupuesto del proyecto 71K€

Descripción del proyecto Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to diagnose AD, expensive, invasive with multiple side effects. Positron Emission Tomography (PET) scans the patient’s brain after being injected with a radioactive marker (cost of €1500) which can cause major allergic reactions. The other method analyzes the cerebrospinal fluid, which requires performing the patient a lumbar puncture. This procedure (relatively expensive, €400) can cause severe headaches, temporary pain of numbness to legs, infections and bleeding into the spinal canal. There are more than 30 million people living with AD in Europe and more than 7 million people that have not received a diagnostic due to the cost and side effects of the current techniques. Without diagnostic, patients lacks of a proper treatment that improves patients life quality ameliorating the symptoms of the disease. The earlier the diagnosis, the earlier the treatment delaying nursery admission. Our solution consists of performing RS onto a sample of blood plasma. It is not invasive, has absolutely no side effects and an estimated selling price of €100. Our solution, making AD diagnosis more affordable, can produce net saving of €2,8bn to the European Healthcare system only delaying institutionalization. Our aim is to bring our solution into the market as a reference diagnostic method for screening patients for Alzheimer’s Disease. Alzheimer Disease is a huge problem that Europe needs to address due to the aging population. By 2050, 50% of the total European population will be over 65 years old and more importantly, 1 out 3 will suffer from Alzheimer’s Disease.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores